The protective role of dapagliflozin on the noreflow phenomenon in type 2 diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention

This publication has 8 references indexed in Scilit:

• Effect of dapagliflozin on the no-reflow phenomenon in patients with acute myocardial infarction and type II diabetes mellitus
  Acta Cardiologica, 2025
• Newly defined biomarker for the no reflow phenomenon in patients with non-ST elevation acute coronary syndrome; uric acid to creatinine ratio
  Acta Cardiologica, 2025
• Association between the triglyceride-glucose index and the severity of coronary artery disease in patients with type 2 diabetes mellitus and coronary artery disease: a retrospective study
  Acta Cardiologica, 2024
• Predictive effect of triglyceride-glucose index on No-Reflow Phenomenon in patients with type 2 diabetes mellitus and acute myocardial infarction undergoing primary percutaneous coronary intervention
  Diabetology & Metabolic Syndrome, 2024
• Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes
  Experimental and Clinical Endocrinology & Diabetes, 2018
• Effect of preoperative loading dose ticagrelor and clopidogrel on no-reflow phenomenon during intervention in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis
  Drug Design, Development and Therapy, 2018
• Prediction of no‐reflow and major adverse cardiovascular events with a new scoring system in STEMI patients
  Journal of Interventional Cardiology, 2017
• Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus
  World Journal of Diabetes, 2015